A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• The International Prognostic Index (IPI) and National Comprehensive Cancer Network-IPI (NCCN-IPI) have limitations in predicting outcomes for diffuse large B-cell lymphoma (DLBCL) patients undergoing immunochemotherapy.
• Accurate prognostication is crucial for tailoring treatment strategies in DLBCL.

Purpose of the Study:

• To develop and validate a modified prognostic model (M-PM) for improved risk stratification in DLBCL patients treated with RCHOP or similar regimens.
• To identify high-risk DLBCL patients who may benefit from more aggressive therapeutic approaches.

Main Methods:

• Retrospective analysis of 169 newly diagnosed DLBCL patients treated between 2011-2017 with RCHOP-like regimens.
• Comparison of the predictive accuracy of the traditional IPI, NCCN-IPI, and the newly developed M-PM.
• The M-PM incorporates age (≥65 years), elevated lactate dehydrogenase, Eastern Cooperative Oncology Group performance status (ECOG ≥2), and total metabolic tumor volume (TMTV ≥300 cm³).

Main Results:

• The NCCN-IPI showed improved risk discrimination over the IPI, but still failed to adequately identify high-risk DLBCL patients.
• The M-PM stratified patients into four risk groups with distinct 5-year overall survival rates (92.4%, 70.6%, 52.3%, and 24.5%).
• The M-PM demonstrated superior accuracy in predicting adverse prognosis for DLBCL patients compared to both IPI and NCCN-IPI.

Conclusions:

• The developed M-PM is a more accurate tool for identifying high-risk DLBCL patients requiring intensive treatment.
• This novel model enhances prognostic assessment in the era of immunochemotherapy for DLBCL.
• The M-PM's components (age, LDH, ECOG, TMTV) offer valuable insights for clinical decision-making in DLBCL management.